Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A

NCT ID: NCT02888223

Last Updated: 2016-09-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-09-30
• Study Completion Date: 2017-07-31

Brief Summary

Participants will be assigned to A or B groups with a scale of 1:1 based on a prospectively randomized treatment-sequence assignment, i.e. infuse SCT800 followed by Xyntha (group A), or the alternate sequence (group B). All participants who completed the SCT800HA1 study will enter the efficacy and safety study (Protocol No.: SCT800HA3).

Conditions

Hemophilia A

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A

a single dose administration of SCT800 followed by Xyntha (50 IU.kg-1, based upon the manufacturer's labeled potency)

Group Type: EXPERIMENTAL

SCT800

Intervention Type: BIOLOGICAL

Xyntha

Intervention Type: BIOLOGICAL

Group B

a single dose administration of Xyntha followed by SCT800(50 IU.kg-1, based upon the manufacturer's labeled potency)

Group Type: EXPERIMENTAL

SCT800

Intervention Type: BIOLOGICAL

Xyntha

Intervention Type: BIOLOGICAL

Interventions

SCT800

Intervention Type: BIOLOGICAL

Xyntha

Intervention Type: BIOLOGICAL

Other Intervention Names

Recombinant human coagulation factor VIII; Antihemophilic Factor (Recombinant), Plasma/Albumin-Free

Eligibility Criteria

Inclusion Criteria

• 12 to 65 years old;
• The activity of the coagulation factor VIII (FVIII:C) ≤2%, and was previously treated with FVIII concentrate(s) for a minimum of 50 exposure days (EDs) prior to study entry
• Non-bleeding state (No clinical manifestations of active hemorrhage);
• Negative assays for FVIII inhibitors (<0.6 BU/mL);
• The platelet count is normal；
• Normal prothrombin time or INR ≤1.5；
• Given informed consent

Exclusion Criteria

• Hypersensitivity to recombinant coagulation factor VIII concentrate or any of the excipients ;allergic to heterologous proteins (e.g. murine, bovine or hamster origin);
• Family history or history of FVIII inhibitors (≥0.6 Bethesda Units [BU] mL-1);
• Received an infusion of any FVIII for on-demand therapy or prophylaxis within 4 days prior to study entry (including rFVIII, plasma-derived factor VIII [pdFVIII], cryoprecipitate and whole blood);
• Significant hepatic or renal impairment (ALT and AST ≥2×ULN; BUN and Cr≥2×ULN);
• HIV seropositive;
• Abnormal hemostasis from causes other than hemophilia A；
• Patients with severe heart disease, including myocardial infarction, heart failure (III or higher level);
• Patients who received any anticoagulant or antiplatelet therapy within one week (including NSAIDs) or need to receive an anticoagulant or antiplatelet therapy during the period of clinical trials;
• Alcoholism, drug abuse, mental disorders and mental retardation;
• Elective surgery planned during the process of study;
• Patients who previously participated in the other clinical trials prior to study entry;
• The patient or parent/legal guardian is unable or unwilling to sign an informed consent form or to comply with the requirements of clinical protocol;
• Other conditions confirmed by the researchers, resulting in that patients are unable to benefit from clinical observation;

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sinocelltech Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xie lan Zhao, PhD

Role: PRINCIPAL_INVESTIGATOR

Xiangya Hospital of Centre-South University, Changsha, China

Locations

Xiangya Hospital of Centre-South University

Changsha, Hunan, China

Countries

China

Facility Contacts

Peijun Xiao

Role: primary

cancergcp@163.com

86-731-84327919

Other Identifiers

SCT800HA1

Identifier Type: -

Identifier Source: org_study_id